SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
SEPTEMBER 9, 2002
CUBIST PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-21379 22-3192085
- ----------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
65 HAYDEN AVENUE, LEXINGTON, MASSACHUSETTS 02421
---------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (781) 860-8660
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(C) EXHIBITS.
99.1 Transcript of September 9, 2002 conference call
ITEM 9. REGULATION FD DISCLOSURE.
On September 9, 2002, the Registrant webcast a telephone conference
regarding the termination of the license agreement between the Registrant and
Gilead Sciences. The conference call transcript has been filed as an exhibit to
this Report on Form 8-K, attached hereto as Exhibit 99.1.
The attached transcript is not "filed" pursuant to the Securities
Exchange Act and is not incorporated by reference into any Securities Act
registration statements. Additionally, the submission of this report on Form 8-K
is not an admission as to the materiality of any information in this report that
is required to be disclosed solely by Regulation FD.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CUBIST PHARMACEUTICALS, INC.
By: /s/ THOMAS A. SHEA
-------------------------------
Thomas A. Shea
Vice President Finance and
Administration, Chief Financial
Officer, Treasurer
Dated: September 10, 2002